Meet with our official CSIRO 2023 BIO-International Convention delegation in Boston from 5 – 8 June. Learn about CSIRO capabilities from biomedical manufacturing to disease surveillance, through to clinical trials in Australia’s leading national facilities.
CSIRO is one of the largest and most multidisciplinary research and technology organisations in the world, with over 5,000 people working across 53 sites globally. We manage state-of-the-art research facilities for the nation, including our advanced National Vaccine and Therapeutics Lab and the Australian Centre for Disease Preparedness, where we test, design and partner to bring great discoveries to life, progress to clinical trials and out to global markets. This includes:
- Customised biomedical manufacturing solutions, supporting the scale-up of vaccines and therapeutics
- Disease surveillance, preparedness and connected vaccine production
- Comprehensive clinical trials and game-changing clinical research
We partner with small and large companies, government and industries to successfully bring innovation to community.
Chat with one of our Bio 23 delegation to learn more.
Meet the Bio-International Convention 2023 delegation
Erica Kneipp
Research Director, Human Health
Erica Kneipp’s experience spans all levels of government, the private and not-for-profit health sectors in Australia and she is known for her passion for evidence-based policy development and research praxis, health systems reform and talent as a research enabler and champion of translation and commercialisation. Erica Kneipp | LinkedIn
Dr Judy Scoble
Group Leader, Biologics Research and Development
Dr Judy Scoble is a Senior Scientist and Group Leader for Biologics Research and Development, within the Biomedical Manufacturing Program at CSIRO. After completing her PhD at La Trobe University and Post Doctoral appointments at the University of Melbourne, La Trobe University and Monash University she joined CSIRO in 2008 as a Research Scientist. She became Team Leader in 2011 and Group Leader in 2022. Judy Scoble | LinkedIn
Anita van der Meer
Director, Business Development
Anita brings over 20 years of clinical commercialisation experience and connections in public health and the private sector including multinational pharmaceutical and medical technology companies and start-ups. Anita van der Meer | LinkedIn
Dr Branwen Morgan
Lead, Minimising Antimicrobial Resistance Mission
Over the last fifteen years, Branwen has held numerous senior communications and project management roles that bridge academic organisations, publicly listed companies, government and NGOs in the UK and Australia. She has a PhD in neuroscience conducted at Sydney's Garvan Institute of Medical Research and has worked in mainstream media and science publishing.
Branwen joined CSIRO in January 2021 as Antimicrobial Resistance (AMR) Mission lead having spent the previous three years at the University of Technology Sydney. Branwen Morgan | LinkedIn
Dharmini Robertson
CSIRO Counsellor for the USA and Canada
Dharmini has over 18 years’ experience working across both the private and public sectors. Prior to joining CSIRO, she led a team developing Australia’s low emissions technology strategy and associated government policies, supporting Dr. Alan Finkel AC in his role as the Australian Government’s special advisor on low emissions technologies. She also advised the Australian Government on innovation policies to assist in commercialising Australia’s research and development. Dharmini Robertson | LinkedIn
Dr Warwick Locke
Team Leader Diagnostics Development, Human Health
Experienced Research scientist with a demonstrated history of working in the research industry. Skilled in Scientific Presentation, Bioinformatics, Statistical Data Analysis, and Genomics. Warwick Locke | LinkedIn
Mary Frey
Commercialisation Manager
Mary Frey’s professional background has been in the area of immunodiagnostics and related product fields which led to a number of successful USA patents and scientific publications. More recently her focus has been on management, joint venture agreements and capital fund raising for start up organisations. Her commercial origins were in R&D companies which were University based both in the USA and Australia and in conjunction with joint-ventures between CSIRO and industry. Mary Frey | LinkedIn